CEL-SCI Corporation (NYSEMKT:CVM) announced that it has received approval from the Medicines and Medical Device Agency of Serbia to begin enrollment of subjects in its Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine* (Leukocyte Interleukin, Injection). Serbia is the 11th country from which approval to participate in the world’s largest Phase III trial for the treatment of head and neck cancer has been obtained. The clinical sites in Serbia are expected to become active in the next few weeks. Approximately 72 of the worldwide total of 880 patients for the study are expected to be enrolled in Serbia. CEL-SCI Corporation (NYSEMKT:CVM) stock opened at $1.12 in last trading session, and closed at $1.07, trading in the range of $1.02 – $1.12. The stock showed a positive/negative weekly performance of 17.58%.
Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN)’s stock had its “neutral” rating reiterated by stock analysts at UBS AG in a report issued on Monday, American Banking and Market News reports. They currently have a $3.50 price target on the stock, down from their previous price target of $6.50. UBS AG’s target price suggests a potential upside of 5.74% from the company’s current price. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) shares closed at $3.67 on last trade day, by losing -6.85%. Stock 52 week range is $2.26 – $10.17. Company’s market capitalization is $354.68 billion.
One company that should be on your radar is XOMA Corp (NASDAQ:XOMA). The stock of the biomedical space has seen its Zacks Rank surge over the past four weeks, moving from Sell territory to its current position as a Buy. A key reason for this move has been the positive trend in the earnings estimate revisions picture. For XOMA’s full year estimate, we have not seen any estimate revision in the past 30 days. However, the consensus estimate trend has been favorable, narrowing from a loss of $1.06 per share a month ago to its current level at $1.05 per share. XOMA Corp (NASDAQ:XOMA) stock decreased -9.84% and finished the last session at $7.51. The EPS of the stock remained – 0.80. Company’s market capitalization is $778.23 billion.
Therapeutics, Inc. (NASDAQ:CLDX) Average Recommendation is Buy with Average Target Price of $37.75. Therapeutics, Inc. (NASDAQ:CLDX) stock opened at $28.36 in last trading session and closed at $27.14. The 52 week range of the stock is $6.90 – $38.84 and the day range was $27.00 – $28.87.